46,011 Shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Bought by XTX Topco Ltd

XTX Topco Ltd acquired a new position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) in the 1st quarter, HoldingsChannel reports. The fund acquired 46,011 shares of the biopharmaceutical company’s stock, valued at approximately $88,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Unified Investment Management boosted its position in shares of Akebia Therapeutics by 47.8% during the 1st quarter. Unified Investment Management now owns 17,000 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 5,500 shares in the last quarter. TD Waterhouse Canada Inc. boosted its position in shares of Akebia Therapeutics by 8.8% during the 4th quarter. TD Waterhouse Canada Inc. now owns 98,618 shares of the biopharmaceutical company’s stock worth $187,000 after acquiring an additional 8,000 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Akebia Therapeutics by 8.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 137,905 shares of the biopharmaceutical company’s stock worth $263,000 after acquiring an additional 11,257 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Akebia Therapeutics by 10.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 126,380 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 12,232 shares in the last quarter. Finally, Mariner LLC acquired a new position in shares of Akebia Therapeutics during the 4th quarter worth about $28,000. 33.92% of the stock is owned by institutional investors and hedge funds.

Akebia Therapeutics Stock Down 1.2%

Shares of NASDAQ AKBA opened at $3.25 on Friday. The stock has a market cap of $861.72 million, a PE ratio of -19.12 and a beta of 0.96. The company has a quick ratio of 1.84, a current ratio of 1.98 and a debt-to-equity ratio of 1.61. Akebia Therapeutics, Inc. has a 52-week low of $1.24 and a 52-week high of $4.08. The business has a 50-day moving average price of $3.66 and a 200 day moving average price of $2.73.

Analyst Ratings Changes

AKBA has been the subject of several analyst reports. Leerink Partnrs raised Akebia Therapeutics to a “strong-buy” rating in a research report on Monday, April 28th. HC Wainwright initiated coverage on Akebia Therapeutics in a research report on Wednesday, June 4th. They issued a “buy” rating and a $8.00 target price for the company. Leerink Partners initiated coverage on Akebia Therapeutics in a research report on Monday, April 28th. They issued an “outperform” rating and a $7.00 target price for the company. Finally, Wall Street Zen raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 3rd. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Akebia Therapeutics has a consensus rating of “Buy” and a consensus target price of $6.75.

Insider Activity at Akebia Therapeutics

In other Akebia Therapeutics news, CFO Erik Ostrowski sold 41,314 shares of the company’s stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $3.67, for a total transaction of $151,622.38. Following the completion of the sale, the chief financial officer directly owned 503,586 shares of the company’s stock, valued at $1,848,160.62. This represents a 7.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Richard C. Malabre sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $4.01, for a total value of $60,150.00. Following the sale, the chief accounting officer directly owned 266,914 shares of the company’s stock, valued at approximately $1,070,325.14. This represents a 5.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,648 shares of company stock valued at $258,841. 3.00% of the stock is owned by company insiders.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.